Other Corporate Information

• 27 Aug, 2024
  Spago Nanomedicals fas I/IIa-studie Tumorad-01 fortsätter efter framgångsrikt slutförd behandling av första patientgruppen
• 27 Aug, 2024
  Spago Nanomedical’s Phase I/IIa study Tumorad-01 continues following successful treatment completion of first patient group
• 20 May, 2024
  Spago Nanomedical uppdaterar om Tumorad-01 – studien framskrider enligt plan
• 20 May, 2024
  Spago Nanomedical provides an update on Tumorad-01 – trial proceeds as planned
• 24 Apr, 2024
  Spago Nanomedical rapporterar gynnsamma data i bröstcancermodell med Tumorad
• 24 Apr, 2024
  Spago Nanomedical reports favorable data in breast cancer model with Tumorad
• 10 Jan, 2024
  Spago Nanomedical går vidare till nästa dosnivå i fas I/IIa-studien Tumorad-01
• 10 Jan, 2024
  Spago Nanomedical proceeds to the next dose level in the phase I/IIa study Tumorad-01
• 15 Dec, 2023
  Spago Nanomedical rapporterar positiva topline-data från den kliniska fas 2a studien SPAGOPIX-02 i patienter med endometrios
• 15 Dec, 2023
  Spago Nanomedical reports positive top line data from clinical phase IIa study SPAGOPIX-02 in patients with endometriosis